3.17MMarket Cap-0.08P/E (TTM)
1.220High1.050Low151.29KVolume1.200Open1.190Pre Close169.35KTurnover6.34%Turnover RatioLossP/E (Static)2.76MShares10.66552wk High0.19P/B2.74MFloat Cap1.05052wk Low--Dividend TTM2.39MShs Float6469632.000Historical High--Div YieldTTM14.29%Amplitude1.050Historical Low1.119Avg Price1Lot Size
TNF Pharmaceuticals Stock Forum
📊⚡️📊
Tnf Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference
1 MINUTE AGO, 9:10 AM EDT
VIA BUSINESSWIRE
Prevail Partners, LLC investment priced at more than a 40% premium to market
Prevail InfoWorks, Inc. to act as Clinical Research Organization partner; global full service CRO with hundreds of clinical trials over a decade
TNF Pharmaceuticals fully funded for clinical trials for next two years
No comment yet